Nanomedicine has emerged to be a promising platform for cancer treatment with reduced side effect and increased therapeutic effect. In recent decades, with the advances in nanobiotechnology, much progress has been achieved in the development and clinical translation of cancer nanomedicines. Until now, several types of nanomedicines have been approved for cancer treatment in clinical and more candidates are in clinical trial. However, it is still a challenge for nanomedicines to treat tumors due to the complexity and heterogeneity nature of tumors. Herein, we summarize the current status and progress of cancer nanomedicines in clinical translation as well as discuss the challenge and future perspective.

nanomedicines  /  cancer  /  drug delivery systems  /  targeted therapy  /  clinical translation